Genicular Artery Embolization for the Treatment of Knee Osteoarthritis

Not Applicable

Completed

Conditions: Degenerative Joint Disease of Knee
Knee Osteoarthritis

Interventions: Device: Embozene MicroSpheres

Registration Number: NCT03491397

Lead Sponsor: Siddharth Padia, MD

Brief Summary: The purpose of this clinical research study is to examine whether Embozene treatment of the genicular artery is a safe and effective way to treat arthritic knee pain. Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.

Detailed Description: This is a phase 2, single-center, prospective, single arm investigational study to evaluate the safety and efficacy of genicular artery embolization (GAE) for treatment of symptomatic knee osteoarthritis (OA). Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres. The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain. The primary objective of this investigation is to assess safety of genicular artery embolization (GAE) for knee osteoarthritis (OA) using Embozene particles.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 40

Inclusion Criteria

Provided informed consent
Age ≥ 40 years and ≤ 80 years
Life expectancy greater than 12 months
Ineligibility for or refusal of surgical management
Moderate-severe knee pain as determined by visual analog scale > 4
Osteoarthritis based on xray
Local knee tenderness
Resistant/failed conservative treatment (e.g. NSAIDS/physical therapy/steroid joint injection)

Exclusion Criteria

• Mild knee pain as determined by visual analog scale < 4

Chronic renal insufficiency (serum creatinine >2 mg/dL)
Uncorrectable bleeding diathesis: international normalized ratio (INR) >1.6, Platelets <50,000
Significant arterial atherosclerosis that would limit selective angiography
Allergy to iodinated contrast agents that is not responsive to steroid management
Active Infection or malignancy
Appropriate candidate for knee replacement surgery determined by clinical and physical examination
Recent (within 3 months) or active cigarette use

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
GAE OA	Embozene MicroSpheres	Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres. The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain.

Primary Outcome Measures

Name	Time	Method
Number of Participants Experiencing Treatment-related Adverse Events, as a Measure of Safety	Up to 12 Months after GAE	Treatment-related AEs from gennicular artery embolization during the study period

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) as a Measure of Efficacy	Baseline, Month 1, Month 3, Month 6, Month 12	The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a self-administered questionnaire consisting of 24 items divided into 3 subscales. Each item is scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). With a total possible range of 0-96, higher scores indicate worse pain, stiffness, and functional limitations. Pain (5 items, possible range 0-20): during walking, using stairs, in bed, sitting or lying, and standing upright Stiffness (2 items, possible range 0-8): after first waking and later in the day Physical Function (17 items, possible range 0-68): using stairs, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy domestic duties, light domestic duties
Change From Baseline in Visual Analog Scale (VAS) as a Measure of Efficacy	Baseline, Month 1, Month 3, Month 6, Month 12	The patient-reported severity of knee pain was quantified using a visual analog scale (VAS) score ranging from 0 (indicating no pain) through 10 (indicating the worst pain imaginable).
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Pain Subscale as a Measure of Efficacy	Baseline, Month 1, Month 3, Month 6, Month 12	The WOMAC Pain Subscale is a self-administered questionnaire of 5 items to assess Pain: during walking, using stairs, in bed, sitting or lying, and standing upright. Each item is scored on a scale of 0-4: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4), with a possible total score range of 0-20.